Proposal of the Election Committee regarding members of the Board etc. for Vitrolife AB (publ)

The Election Committee of Vitrolife, which was appointed in accordance with the
resolution of the Annual General Meeting on May 5, 2014, consists of:

Patrik Tigerschiöld, representing Bure Equity AB
Thomas Olausson
Martin Lewin, representing Eccenovo AB
Carsten Browall, Chairman of the Board

The Election Committee proposes the following to the Annual General Meeting of
Vitrolife that will take place on Tuesday May 5, 2015:

-  that the Chairman of the meeting shall be Carsten Browall.

-  that the members of the Board shall be six in number.

-  that the Board remuneration shall be SEK 1,440,000, of which SEK 450,000 to
the Chairman of the Board, SEK 150,000 to each of the other members of the
Board. SEK 60,000 to the Chairman of the Audit Committee, SEK 60,000 to the
Chairman of the Remuneration Committee and SEK 30,000 to the other members of
these committees. The proposal equals an increase of SEK 330.000 of the total
amount compared to the previous year.

-  re-election of the Board members Fredrik Mattsson, Tord Lendau, Barbro
Fridén, Pia Marions and Carsten Browall and election of the new Board member Jón
Sigurdsson (CEO Össur). Maris Hartmanis has declined re-election.

-  re-election of Carsten Browall as Chairman of the Board.

-  that a new Election Committee be set up for the Annual General Meeting of
2016. It is proposed that the Election Committee is appointed in the same way as
previously, whereby the Chairman of the Board contacts the three largest
registered shareholders or otherwise known owners at the end of the third
quarter of 2015 and asks them to appoint one member each. The three members who
are appointed and the Chairman of the Board constitute the Election Committee.
The Election Committee appoints a Chairman internally.
Contact:

Patrik Tigerschiöld, Chairman of the Election Committee, phone +46 8 614 00 20
Carsten Browall, Chairman of the Board, phone +46 70 255 65 32

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on March
30, 2015 at 11:00 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
________________________________

Vitrolife (http://www.vitrolife.com/en/Corporate/) is an international medical
device Group. Vitrolife Fertility (http://www.vitrolife.com/en/Fertility/)
product area develops, produces and markets medical devices for assisted
reproduction. Work is also carried out to enable the use and handling of stem
cells for therapeutic purposes

Vitrolife (http://www.vitrolife.com/en/Corporate/) has approximately 330
employees and the company's products are sold in almost 110 markets. The company
is headquartered in Gothenburg, Sweden, and there are also offices in USA,
Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The
Vitrolife share (http://www.vitrolife.com/en/Corporate/Financial/The-share1/) is
listed on NASDAQ OMX
Stockholm (http://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=SSE
1 
3469), Mid Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail:
info@vitrolife.com. Website: www.vitrolife.com/